Eledon Pharmaceuticals Overview: Clinical-Stage Biotech Focused on CD40L Pathway Therapies

Eledon Pharmaceuticals (Nasdaq: ELDN) develops tegoprubart, an IgG1 anti-CD40L antibody designed to prevent organ transplant rejection with its mission of One Transplant for Life.